{"id": "179466", "url": "https://fevir.net/resources/Composition/179466", "date": "2026-01-26T20:41:33.583Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"], "versionId": "50", "lastUpdated": "2026-01-26T20:41:33.583Z"}, "type": {"coding": [{"code": "Recommendation", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Recommendation"}]}, "title": "Recommendation: ADA Obesity Management Recommendation 8.16", "author": [{"type": "Practitioner", "display": "Brian S. Alper"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "Example of Recommendation Profile of Composition Resource."}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Recommendation: ADA Obesity Management Recommendation 8.16 [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179466. Revised 2026-01-26. Available at: https://fevir.net/resources/Composition/179466. Computable resource at: https://fevir.net/resources/Composition/179466#json."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "179466", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"code": {"text": "overallSummary", "coding": [{"code": "recommendation-statement", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Recommendation Statement"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>8.16 Metabolic surgery should be a recommended option to treat type 2 diabetes in screened surgical candidates with BMI \u226540 kg/m2 (BMI \u226537.5 kg/m2 in Asian Americans) and in adults with BMI 35.0\u201339.9 kg/m2 (32.5\u201337.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</p></div>", "status": "additional"}, "title": "Recommendation Statement"}, {"code": {"text": "overallRatings", "coding": [{"code": "ratings", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Ratings"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A</div>", "status": "generated"}, "entry": [{"type": "ArtifactAssessment", "display": "Recommendation Rating: ADA Obesity Management Recommendation 8.16 (385882)", "reference": "ArtifactAssessment/385882"}], "title": "Recommendation Ratings"}, {"code": {"text": "population", "coding": [{"code": "population", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Population"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) \u2265 40.0 kg/m2 (BMI \u2265 37.5 kg/m2 in Asian Americans), or BMI \u2265 35.0 kg/m2 and \u2264 39.9 kg/m2 (BMI 32.5-37.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.</div>", "status": "generated"}, "entry": [{"type": "Group", "display": "RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)", "reference": "Group/32139"}], "title": "Population"}, {"code": {"text": "action", "coding": [{"code": "action", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Action"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Metabolic surgery is recommended.</div>", "status": "generated"}, "entry": [{"type": "PlanDefinition", "display": "PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16", "reference": "PlanDefinition/179468"}], "title": "Action"}, {"code": {"text": "oppositeAction", "coding": [{"code": "opposite-action", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Opposite Action"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Opposite Action", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "introduction", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Introduction"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Introduction Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "justification", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Justification"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><strong>Title: </strong>Justification for Recommendation: ADA Obesity Management Recommendation 8.16</p>\n<p><strong>Justification for Recommendation: </strong>Recommendation: ADA Obesity Management Recommendation 8.16</p>\n<table>\n    <tbody>\n        <tr>\n            <th>Concept</th>\n            <th>Summary</th>\n            <th>Rating</th>\n        </tr>\n        <tr>\n            <td>Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td>\n            <td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td>\n            <td>undefined</td>\n        </tr>\n        <tr>\n            <td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td>\n            <td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td>\n            <td>undefined</td>\n        </tr>\n        <tr>\n            <td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td>\n            <td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<p> &#160; &#160; </p>\n         In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.\n            </td>\n            <td>undefined</td>\n        </tr>\n        <tr>\n            <td>Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td>\n            <td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes\u20142021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose.<p> &#160;  &#160; </p>NOTE: The disclosed conflicts of interest was not found at the suggested URL</td>\n            <td>undefined</td>\n        </tr>\n    </tbody>\n</table></div>", "status": "additional"}, "entry": [{"type": "ArtifactAssessment", "display": "Justification for Recommendation: ADA Obesity Management Recommendation 8.16", "reference": "ArtifactAssessment/179469"}], "title": "Justification"}, {"code": {"coding": [{"code": "considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Considerations"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>", "status": "empty"}, "title": "Considerations", "section": [{"code": {"text": "overallConsiderationsSummary", "coding": [{"code": "summary", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Summary"}]}, "title": "Overall Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "subgroupConsiderationsSummary", "coding": [{"code": "subgroup-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Subgroup Considerations"}]}, "title": "Subgroup Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "implementationConsiderationsSummary", "coding": [{"code": "implementation-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Implementation Considerations"}]}, "title": "Implementation Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "monitoringConsiderationsSummary", "coding": [{"code": "monitoring-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Monitoring Considerations"}]}, "title": "Monitoring Considerations Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"text": "competingInterestsSummary", "coding": [{"code": "competing-interests", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Competing Interests"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes\u20142021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</div>", "status": "generated"}, "entry": [{"type": "ArtifactAssessment", "reference": "ArtifactAssessment/179469"}], "title": "Competing Interests Summary"}, {"code": {"text": "researchConsiderationsSummary", "coding": [{"code": "research-considerations", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Research Considerations"}]}, "title": "Research Priorities Summary", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}, {"code": {"coding": [{"code": "methods", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Methods"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Methods Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "evidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</div>", "status": "additional"}, "entry": [{"type": "ArtifactAssessment", "reference": "ArtifactAssessment/179469"}], "title": "Evidence"}, {"code": {"coding": [{"code": "discussion", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Discussion"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Discussion", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "references", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "References"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "References Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "competing-interests", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Competing Interests"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Competing Interests Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "acknowledgements", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Acknowledgements"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Acknowledgements Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}, {"code": {"coding": [{"code": "appendices", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Appendices"}]}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>", "status": "empty"}, "title": "Appendices Section", "emptyReason": {"coding": [{"code": "notstarted", "system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "display": "Not Started"}]}}]}